Skip to content

Unraveling the Klinefelter's Disease Physiopathology

Unraveling the Klinefelter's Disease Physiopathology by Organoid Model

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05997706
Acronym
KLINEFELTER
Enrollment
20
Registered
2023-08-18
Start date
2018-06-12
Completion date
2025-04-01
Last updated
2023-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Male, Klinefelter Syndrome

Keywords

Klinefelter Syndrome, fertility preservation, male

Brief summary

Organoid Model to unravel Klinefelter Syndrome infertility Klinefelter Syndrome (KS) is characterized by the presence of an extra chromosome X in male (47,XXY), it is the most frequent genetic cause of azoospermia in adult men. The investigators will isolate and expand spermatogonial cells from KS patients, then using an organoid model investigators will compare the behavior of these Spermatogonia from KS patients when interacting with four combinations of somatic cell types incorporated in the Extra Cellular Matrix hydrogel.

Detailed description

Men with Klinefelter Syndrome candidate for TESE or microTESE (testicular sperm extraction) for azoospermia. One extra testicular biopsy (1-2 mm) will be cryopreserved and used later for the cells isolation and culture.

Interventions

Testicular biopsy is a clinical procedure for extraction of testicular tissue

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
5 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Klinefelter

Exclusion criteria

* Mosaicism

Design outcomes

Primary

MeasureTime frameDescription
Klinefelter's infertility physiopathologyUp to 60 days with intermediate time analyses at the 5th and 10 th passage of cultures.Testicular biopsies will be digested using two steps enzymatic protocol. Cell suspensions will be in vitro cultured during 2 months. The following analyses will be performed: cells counts, cells characterisation by immunofluorescence and RTqPCR specific for the cell type, cells karyotypes.

Countries

Belgium

Contacts

Primary ContactChristine Wyns, MD, PhD
christine.wyns@uclouvain.be+3227649501
Backup ContactMaria Grazia Giudice, MD
maria.giudice@uclouvain.be+32485256903

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026